GlassScriptPhysician profile
Scott D Glazer
NPI 1770587206
$37,737.33
in general payments reported to CMS, 2019-2025
34 companies · $4,787 in 2025
The $4,787 reported for 2025 was more than what 88% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $682 · 2021: $5,135 · 2022: $17K · 2023: $4,484 · 2024: $4,473 · 2025: $4,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,127 · Food and Beverage: $4,568 · Education: $49.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,127.22 |
| Food and Beverage | $4,567.66 |
| Education | $49.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19,423.11 | 2019-2023 | |
| Abbvie INC. | $10,861.27 | 2019-2025 | |
| Epi Health, LLC | $1,533.84 | 2022 | |
| Janssen Biotech, INC. | $896.64 | 2019-2025 | Simponi Aria, Simponi, Tremfya |
| Genzyme Corporation | $718.42 | 2022-2025 | |
| Revance Therapeutics, INC. | $545.22 | 2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $437.26 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $395.32 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $333.86 | 2020-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $318.27 | 2020-2025 | Aklief, Dysport, Nemluvio |
| Amgen INC. | $305.22 | 2022-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $255.22 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $197.20 | 2023-2025 | Sotyktu |
| Merz North America, INC. | $181.40 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $164.65 | 2024-2025 | Zoryve |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $149.44 | 2024-2025 | Adbry |
| Pfizer INC. | $138.30 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $137.06 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $109.98 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.73 | 2022-2025 | Spevigo |
| Genentech USA, INC. | $87.58 | 2019-2024 | Erivedge |
| Incyte Corporation | $76.24 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $57.22 | 2023 | Vtama |
| Mallinckrodt Hospital Products INC. | $53.50 | 2025 | Acthar |
| Kyowa Kirin, INC. | $41.66 | 2020 | |
| Smith+Nephew, INC. | $38.20 | 2024 | Grafix Pl |
| Verrica Pharmaceuticals INC. | $28.68 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.48 | 2019-2021 | |
| Organon LLC | $27.23 | 2025 | Vtama |
| Organogenesis INC. | $26.96 | 2023 | Puraply |
| Janssen Scientific Affairs, LLC | $26.55 | 2019 | |
| Vyne Pharmaceuticals INC. | $24.26 | 2020 | |
| Biofrontera INC. | $15.13 | 2020 | |
| Mylan Pharmaceuticals INC. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Glazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.